Myobloc / Neurobloc
Myobloc / Neurobloc is the main commercial botulinum toxin type B brand node in this index. The U.S. product name is Myobloc, and its nonproprietary name is rimabotulinumtoxinB. Neurobloc was the corresponding European brand name, though European Medicines Agency materials describe that authorization as withdrawn.
Its role is therapeutic type B reference, not aesthetic type A peer to Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| U.S. brand | Myobloc |
| Other regional name | Neurobloc |
| Nonproprietary name | RimabotulinumtoxinB |
| Toxin type | Botulinum toxin type B |
| U.S. manufacturer and license holder | Solstice Neurosciences, LLC |
| Current commercial owner | Supernus Pharmaceuticals, following its 2020 acquisition of worldwide Myobloc rights from US WorldMeds (Supernus acquisition announcement 🔗) |
| Serotype comparison | Botulinum toxin type A vs type B |
Label Context
Section titled “Label Context”Current U.S. interpretation should stay anchored to Myobloc prescribing information. The product is relevant to therapeutic discussion, especially cervical dystonia and chronic sialorrhea, rather than to the U.S. aesthetic type A comparison set.
Type B biology also affects how readers interpret mechanism, onset discussion, adverse-event framing, and immunogenicity. Those topics require product-specific evidence rather than assumptions from type A products.
Market Interpretation
Section titled “Market Interpretation”Myobloc / Neurobloc keeps the brand map from treating botulinum toxin as only a type A aesthetic category. It gives readers a concrete product-level reference for type B and helps explain why serotype matters.
The type B role does not make Myobloc a direct unit or dose comparator for Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo. Type A and type B products use different biological targets and product-specific potency systems.
Graph Connections
Section titled “Graph Connections”Supernus Pharmaceuticals supplies the current company and portfolio context. Botulinum toxin explains the broader medicine family, while type A vs type B and botulinum toxin type B provide the most relevant serotype context.
Jack A. Khattar anchors the current Supernus company-leadership context, Jonathan Rubin, MD, MBA anchors medical and R&D leadership, and Todd Horich, Ph.D., MBA anchors commercial organization. These people links explain the current company graph, not Myobloc’s original development history.